# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst David Williams reiterates MaxLinear (NASDAQ:MXL) with a Buy and maintains $28 price target.
Needham analyst Quinn Bolton reiterates MaxLinear (NASDAQ:MXL) with a Buy and maintains $25 price target.
MaxLinear (NASDAQ:MXL) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.22) by 4...
Benchmark analyst David Williams maintains MaxLinear (NASDAQ:MXL) with a Buy and raises the price target from $23 to $28.
Northland Capital Markets analyst Tim Savageaux upgrades MaxLinear (NASDAQ:MXL) from Market Perform to Outperform and announ...
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong prelimi...
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-...